ArticleRSC advances2022
Development of a hematite nanotube and tyramine-based drug carrier against drug-resistant bacteria
Article in RSC advances, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
- Applications of Bioinorganic Nano-Based Delivery Systems-Diagnostics and Therapeutics.Drug development research · 2026Review
- Polypyrrole functionalized (TiRSC advances · 2025Article
- Clinical study on modified Shenzhe Zhenqi Decoction combined with ambroxol hydrochloride in the treatment of severe pneumonia.Frontiers in physiology · 2025Article
- Thermo-responsive Bioink for Personalized 3D Printed Scaffolds with Antioxidant and Fibroblast Delivery to Accelerate Diabetic Wound Healing.Biomaterials research · 2025Article
- Bioreceptor modified electrochemical biosensors for the detection of life threating pathogenic bacteria: a review.RSC advances · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this study, hematite nanotube (HNT) and tyramine-based advanced nano-drug carriers were developed for inhibiting the growth of
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.